FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- The Elecsys GALAD score aims to support clinicians in diagnosing hepatocellular carcinoma by giving them more timely and accurate information to make earlier interventions
- When hepatocellular carcinoma is detected and managed at the very earliest, patient?s 5-year survival rates can increase to over 70%1
- Utilizing blood-based biomarkers, as part of the Elecsys GALAD score, is minimally invasive to patients
Attachment